无解决的疗效：mepolizumab在嗜酸性COPD中的关键评价。

IF 11.8 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Med Pub Date : 2025-08-08 DOI:10.1016/j.medj.2025.100784

Mario Cazzola, Maria Gabriella Matera

引用次数: 0

摘要

Mepolizumab可减少嗜酸性COPD的恶化，但对症状、肺功能或生活质量的影响有限。MATINEE试验支持针对高嗜酸性粒细胞计数的精准医学方法然而，由于复杂、重叠的炎症途径和持续的肺内嗜酸性粒细胞，单独阻断IL-5可能是不够的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Efficacy without resolution: A critical appraisal of mepolizumab in eosinophilic COPD.

Mepolizumab reduces exacerbations in eosinophilic COPD but shows limited effects on symptoms, lung function, or quality of life. The MATINEE trial supports a precision medicine approach targeting high blood eosinophil counts.¹ However, IL-5 blockade alone may be insufficient due to complex, overlapping inflammatory pathways and persistent lung-resident eosinophils.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Med MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

17.70

自引率

0.60%

发文量

102

期刊介绍： Med is a flagship medical journal published monthly by Cell Press, the global publisher of trusted and authoritative science journals including Cell, Cancer Cell, and Cell Reports Medicine. Our mission is to advance clinical research and practice by providing a communication forum for the publication of clinical trial results, innovative observations from longitudinal cohorts, and pioneering discoveries about disease mechanisms. The journal also encourages thought-leadership discussions among biomedical researchers, physicians, and other health scientists and stakeholders. Our goal is to improve health worldwide sustainably and ethically. Med publishes rigorously vetted original research and cutting-edge review and perspective articles on critical health issues globally and regionally. Our research section covers clinical case reports, first-in-human studies, large-scale clinical trials, population-based studies, as well as translational research work with the potential to change the course of medical research and improve clinical practice.